Fairmount Funds Management LLC bought $5.1M of Zenas BioPharma (ZBIO)

Executed Sep 16 2024, disclosed Sep 17 2024, 1 day later.

Value, as filed

$5.1M

300,000 sh × $17.00

Executed

Sep 16 2024

the trade date, as filed

Disclosed

Sep 17 2024

1 day after the trade

Return, 21 sessionsiFrom the disclosed entry session; derived

–

not yet measured

Not yet measured: the 21-session window has not closed, or the prices around it are not on record.

The filer

FL Fairmount Funds Management LLC Director profile →

Fairmount Funds Management LLC (Director) filed 10 Form 4 reports as a reporting entity in the trailing twelve months (6 purchases, 4 sales), most often in Cogent Biosciences, Inc. (COGT). Across 6 priced purchase filings, the average 21-session return was +5.9% from execution and +8.5% from disclosure (delay-adjusted; derived). The largest single filing was $399.7M of SYRE (4,684,781 sh × $85.31, as filed), executed Jun 23.

The name

ZBIO

Zenas BioPharma, Inc. ZBIO · Healthcare · 18 filings in 24 months ticker →

Healthcare · Zenas BioPharma, Inc., a clinical-stage biopharma company, engages in the development and commercialization of transformative immunology-ba…

More Healthcare filings→ Insider filings, newest first→ View the original filing at www.sec.gov→

Other filings by Fairmount Funds Management LLC in ZBIO

ZBIOPURCHASE Zenas BioPharma, Inc. $3.0M
150,000 sh × $20.00
Exec Mar 31
Filed Apr 1 · 4:30 PM ET ZBIOPURCHASE Zenas BioPharma, Inc. $6.0M
316,219 sh × $19.00
Exec Oct 7 2025
Filed Oct 9 2025 · 4:15 PM ET